Explore updates on potential GLP-1 uses and risks, including addiction treatment, bone injury concerns, and kidney disease effectiveness.

Diabetes and obesity drugs also lead to large reductions in adverse cardiovascular events, and the benefits aren’t just down ...

Retrospective study finds link between blockbuster drugs and longer survival ...

For the more than 48 million Americans with substance use disorders, including a disproportionate share of veterans, GLP-1 drugs are not yet an approved addiction treatment. But the evidence base is ...

The effect was seen across a wide variety of addictive and habit-forming substances, including cocaine, opioids, alcohol, ...

Sustained GLP-1 receptor agonist therapy is linked to greater improvements in A1c levels than DPP-4 inhibitor therapy in patients with type 2 diabetes, a Danish real-world analysis shows.

A peer-reviewed study of more than 46,000 older adults with type 2 diabetes found that patients who started GLP-1 receptor agonist drugs faced an 11 percent higher risk of fragility fractures compared ...

—Study findings highlight the need for improved recommendations of guideline-directed therapies and support the consideration of dual therapy in appropriately selected high-risk patients. In a study ...

Popular drug class quiets "drug noise," says researcher ...

Taking GLP-1 RAs is associated with fewer hospitalizations overall and less need for medications used to stop and prevent ...

GLP-1 receptor agonist-related agonism may prevent addiction phenotypes across all major drug classes according to authors of a recent study.

A class of medications best known for treating diabetes and obesity may also reduce the risk of addiction – and help people who already have one, a new study shows. Semaglutide (also known as Ozempic) ...